Interferon beta-1a – Communicable Diseases Research

Adverse side effects of Glatiramer acetate and Interferon beta-1a in patients with multiple sclerosis: A systematic review of case reports

Review Paper

Published on 2023-04-042024-09-04
Journal: Science (New York, N.Y.) [Category] 대상포진,

Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials

COVID-19에 대한 새로운 치료법: 더 많은 임상 시험에서 얻은 정보의 가치

Article

Published on 2022-08-012022-09-11
Journal: Value in health : the journal of the International [Category] 임상, 진단,

[키워드] Analysis approval approved Baricitinib benefit Casirivimab clinical clinician Cohort consequence Cost-benefit analysis COVID-19 COVID-19 pandemic decision support techniques Dexamethasone drug approval. effective Emergency use authorization Evidence Health healthcare hospitalized patient hospitalized patients Hydroxychloroquine Imdevimab implementation information interferon interferon beta Interferon beta-1a Lopinavir Lopinavir-ritonavir outcome pandemic Perspective Randomized controlled trial RCT RCTs Remdesivir Research Ritonavir seeking Support therapy threshold Tocilizumab usual care value with COVID-19
[DOI] 10.1016/j.jval.2022.03.016 PMC 바로가기 [Article Type] Article

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial

COVID-19(DisCoVeRy)로 입원한 환자의 치료를 위한 렘데시비르 + 표준 치료 대 표준 치료 단독: 3상, 무작위, 대조, 공개 시험

Clinical Trial

Published on 2022-02-012022-09-11
Journal: The Lancet. Infectious Diseases [Category] Fulltext, MERS, 임상, 치료법, 치료제,

[키워드] Abstract activities activity acute respiratory distress acute respiratory distress syndrome adaptive Administered Adult patient Adult patients Analysis antiviral efficacy assigned Bacterial infection Belgium block Breastfeeding Chronic kidney disease clinical clinical benefit Clinical efficacy clinical evidence Clinical research clinical status Combination Commission computer-generated conducted control group Controlled trial COVID-19 criteria death development discharged distribution elevated elevated liver enzymes eligible enrolled Europe European evaluate evidence of exclusion criteria extracorporeal membrane oxygenation followed by France French group Health care hepatorenal syndrome high flow oxygen devices hospital hospitalised Hydroxychloroquine Inclusion indication Innovation intention-to-treat population interferon interferon beta Interferon beta-1a intravenous intravenous infusion Invasive mechanical ventilation investigators Kidney disease laboratory-confirmed SARS-CoV-2 infection limitation liver enzymes Lopinavir Lopinavir-ritonavir Luxembourg material Ministry of Health modified intention-to-treat multicentre no significant difference non-invasive ventilation not significant Occurrence Odds ratio once daily one health Open-label Ordinal Scale oxygen oxygen supplementation oxygen support participant Patient Phase 3 Pneumonia Portugal Pregnancy Primary outcome random assignment randomisation randomised Randomly receive Regional Registered Remdesivir required requiring supplemental oxygen respiratory distress ribavirin Ritonavir Safety SARS-CoV-2 SARS-COV-2 infection Secondary outcomes Serious Adverse Event Serious Adverse Events seven-point ordinal scale Severity of disease Sponsor Standard of care stratified supplemental oxygen Support symptomatic syndrome the WHO translation Treatment treatment group treatment groups Trial Tumor union ventilator were excluded WHO ordinal scale with COVID-19
[DOI] 10.1016/S1473-3099(21)00485-0 PMC 바로가기 [Article Type] Clinical Trial

Comparing the outcomes of treatment with INF-β 1-a (interferon beta-1a) and IFN-β 1-b (interferon beta-1b) among COVID-19 inpatients

코로나19 입원환자 중 INF-β 1-a(인터페론베타-1a)와 IFN-β1-b(인터페론베타-1b) 치료 결과 비교

Comparative Study

Published on 2021-12-012022-09-11
Journal: International immunopharmacology [Category] SARS, 치료법, 치료제,

[키워드] addition Clinical improvement Clinical treatment COVID-19 COVID-19 treatment discharge drug duration of hospitalization Effect evaluated Factors Frequency hospital Hospital stay Hospitalization ICU ICU admission IFN-β IFNβ Inpatient Inpatients interferon interferon beta Interferon beta-1a Interferon beta-1b intervention group intubation Laboratory mechanical ventilation median medication medications Mortality mortality rate no significant difference Other outcomes outcome outcomes patients with COVID-19 Primary outcome recipient recipients Secondary outcomes significant difference statistically significant study group the disease Treatment two group two groups were assessed
[DOI] 10.1016/j.intimp.2021.108241 PMC 바로가기 [Article Type] Comparative Study

Complex analysis of the personalized pharmacotherapy in the management of COVID-19 patients and suggestions for applications of predictive, preventive, and personalized medicine attitude

Research

Published on 2021-07-162022-10-31
Journal: The EPMA Journal [Category] COVID-19,

[키워드] all ethnic groups alpha-2b analysed Analysis antiviral agent approach Biomarker calculated ceftriaxone Characteristics Chloroquine clinical Clinical practice clinical trial Colchicine collected Comorbidities comprehensive analysis Coronavirus disease 2019 COVID-19 COVID-19 patient daclatasvir defined Dexamethasone drug Drug efficacy Drug score drug therapy Drug-to-drug interaction drugs ethnic group Ethnicity-based differences evaluate facilitate Frequency functional Future healthcare Gene score generate genetic difference genetic differences genetic test HCQ highest human immunoglobulin human immunoglobulin G Hydroxychloroquine immune regulator indicated Individual outcomes individuals interferon interferon alpha-2b Interferon beta-1a levofloxacin Lopinavir losartan management molecular mechanisms Optimal medication patients with comorbidity performed Personalized medicine personalized treatment pharmacogenetic pharmacogenetics pharmacogenomics Predictive Predictive preventive personalized medicine (PPPM/3 PM) Prednisone Remdesivir reported Result ribavirin Ritonavir significantly sofosbuvir suggested supplementary material the patient translation Treatment Trial Variation variations Zinc
[DOI] 10.1007/s13167-021-00247-0 PMC 바로가기 [Article Type] Research

Combination therapy of IFNβ1 with lopinavir-ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients

IFNβ1과 로피나비르-리토나비르의 병용 요법은 중증 COVID-19 감염 환자의 산소 공급, 생존 및 퇴원을 증가시킵니다.

Article

Published on 2021-03-012022-09-11
Journal: International immunopharmacology [Category] 치료제,

[키워드] age all-cause mortality Analysis antiviral effects caused clinical study Combination Comorbidity conducted control group coronavirus COVID-19 COVID-19 patient COVID-19 patients COVID-19 treatment death rate defined determine dose during treatment Efficacy hospital hospitalized patient IFN-β1-a immunomodulatory in vitro activity in vivo increase infection with SARS-CoV-2 inflammatory cells inhibit Inpatient intensive care interferon interferon beta Interferon beta-1a International Lopinavir Lopinavir-ritonavir Lopinavir/ritonavir mediator Mortality Multivariate analysis Noninvasive ventilation outcome Oxygenation patients died receiving remained required Retrospective study risk of death Ritonavir SARS-CoV-2 Sex shown significantly standard care survival the disease therapy Treatment virus was done
[DOI] 10.1016/j.intimp.2020.107329 PMC 바로가기 [Article Type] Article

Repurposed Antiviral Drugs for Covid-19 – Interim WHO Solidarity Trial Results

Covid-19에 대한 용도 변경 항바이러스 약물 - WHO 연대 실험 잠정 결과

Randomized Controlled Trial

Published on 2021-02-112022-09-11
Journal: The New England Journal of Medicine [Category] Fulltext, MERS, 임상, 치료제,

[키워드] (rate ratio 28-day mortality 95% CI 95% confidence interval adherence age Analysis antiviral drug antiviral drugs assigned calculated Care coronavirus disease Coronavirus disease 2019 death drug drug regimen examined FIVE group Health Organization hospital Hospital stay Hospitalization hospitalized patient hospitalized patients Hydroxychloroquine in-hospital mortality indicated Inpatient Inpatients intention-to-treat interferon interferon beta Interferon beta-1a Interim interquartile range ISRCTN registry Kaplan-Meier Local Lopinavir mechanical ventilation median Mortality no effect occurred open overall mortality Pairwise comparison Patient patients hospitalized randomization Randomly rate ratio rate ratios receive receiving reduced regimen Remdesivir reported Result Solidarity trial Standard of care status Stratification the patient Treatment Trial Ventilation WHO World Health Organization
[DOI] 10.1056/NEJMoa2023184 PMC 바로가기 [Article Type] Randomized Controlled Trial

Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial

SARS-CoV-2 감염 치료를 위한 흡입 분무 인터페론 베타-1a(SNG001)의 안전성 및 효능: 무작위 배정, 이중 맹검, 위약 대조, 2상 시험

Clinical Trial

Published on 2021-02-012022-09-11
Journal: The Lancet. Respiratory Medicine [Category] 임상, 치료제,

[키워드] 1:1 activities acute respiratory syndrome acute respiratory syndrome coronavirus adverse event adverse events Analysis assigned clinical clinical condition Clinical improvement clinical trials coronavirus COVID-19 symptoms death dose double-blind during treatment Efficacy Efficacy and safety FIVE greater hazard ratio headache hospital identify improvement Infection inhalation Inhaled Inpatient Inpatients intention-to-treat population interferon Interferon beta-1a MIU Multiple nine no infection Odds ratio Older Ordinal Scale oxygen oxygen supplementation Patient Phase 2 phase 2 trial Placebo placebo group placebo-controlled point-of-care positive RT-PCR Primary outcome randomised Randomly receive receiving Registered reported required respiratory Safety SARS-CoV-2 SARS-COV-2 infection scale Seven severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 statistical study drug substantial risk Symptoms the placebo group the WHO those receiving placebo Treatment treatment-emergent adverse event Trial trials WHO ordinal scale with COVID-19
[DOI] 10.1016/S2213-2600(20)30511-7 PMC 바로가기 [Article Type] Clinical Trial

The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial

경증 및 중등도 COVID-19 환자에서 이버멕틴의 효능 및 안전성: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-01-042022-09-10
Journal: Trials [Category] 임상, 치료제,

[키워드] 1:1 ACE inhibitor ACE inhibitors acute respiratory syndrome Adverse drug reaction Adverse drug reactions AIDS allergy anticipated Anticoagulant Anticoagulants Asthma Bandar Abbas Blinding Breastfeeding Captopril chest X-ray clinical clinical symptom Clinical symptoms clinical trial clinical trials company Computed tomography Confirmed Control control group control groups Controlled trial COVID-19 COVID-19 symptom criteria Critical CXR Department discharge Diseases dissemination dose Drug allergy education Efficacy and safety element evaluate exclusion criteria FIVE France group groups history Hospital stay Hospitalization Hospitalization Mechanical ventilation hydroxychloroquine sulfate ICU admission incidence include inclusion criteria India Infection Informed consent Inpatients Interferon beta-1a intervention group Iran Ivermectin Kidney disease liver loiasis Lopinavir Lopinavir/ritonavir mechanical ventilation Mild mild COVID-19 symptom mild COVID-19 symptoms mild pneumonia Ministry of Health moderate Moderate COVID-19 moderately severe COVID-19 MSD number objective Open-label Other outcome Outpatient outpatients parallel-group participant Patient patients patients with moderate PCR pharmaceutical Pharmaceutical Company Phase 3 Pneumonia Pregnancy Primary outcome Primary outcomes protocol random randomization Randomized Randomized controlled trial receive regimen Registered registration date registration number registry respiratory Ritonavir routine care Sample size secondary outcome selected Seven Severe acute respiratory syndrome single dose single-center standard treatment status Study protocol subsequent supplementary material table the patient Treatment treatment group Trial registration twice a day two group two groups underlying diseases Version Warfarin website weight
[DOI] 10.1186/s13063-020-04988-7 PMC 바로가기 [Article Type] Letter

An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial

Letter

Published on 2020-10-262022-10-29
Journal: Trials [Category] COVID-19, MERS, SARS,

[키워드] 1:1 accompany Admission age alcohol allocation concealment ALT/AST Arm assigned Beta block-randomization Blood body temperature Care clinical Clinical improvement clinical trial comparator Confirmed control group COVID COVID-19 COVID-2019 CT scan death discharge disease dissemination drug duration of hospitalization Effect Effectiveness element eligibility criteria exclusion criteria fatigue group headache Health High dose High-dose hospital hospital discharge Hospitalization improvement incidence include Infection information Interaction interferon beta Interferon beta-1a Interferon-β 1a intervention group Intubated Invasive mechanical ventilation investigator Kaletra Laboratory results lactating women Last less limit Loghman Hakim Hospital Lopinavir/ritonavir low dose low-dose masking mechanical ventilation Medical Sciences moderate Mortality nasal Non-invasive number objective open label Open-label outcome oxygen saturation oxygen support package parallel group participant Patient pregnant Primary outcome primary outcome measure professional protocol R software Radiation randomised randomization randomization sequence Randomized Randomized controlled trial Randomly receive Recigen recruitment refusal regimen Registered Research respiratory rate Ritonavir RT-PCR RT-PCR test Sample size SARS-CoV-2 sealed secondary secondary outcome seven-category ordinal scale severe disease Shortness of breath single center standard care status Study protocol Symptom the patient therapeutic time treated treatment groups Trial two groups university version 3.6.1 website World Health Organization
[DOI] 10.1186/s13063-020-04812-2 PMC 바로가기 [Article Type] Letter